<DOC>
	<DOCNO>NCT01224106</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled parallel-group study evaluate effect gantenerumab ( RO4909832 ) cognition function safety pharmacokinetics participant prodromal Alzheimer 's Disease . Participants randomize receive subcutaneous ( SC ) injection either gantenerumab placebo . Participants consent part sub study undergo positron emission tomography ( PET ) scan assess brain amyloid . The anticipated time study treatment 104 week , option additional 2 year treatment .</brief_summary>
	<brief_title>A Study Gantenerumab Participants With Prodromal Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult participant , 5085 year age Participants prodromal Alzheimer 's disease receive memantine cholinesterase inhibitor Has study partner investigator 's judgement frequent sufficient contact participant able provide accurate information participant 's cognitive functional ability , agree provide information clinic visit require partner input scale completion Has sufficient education work experience exclude mental retardation Study partner notice recent gradual decrease participant 's memory ( last 12 month ) , participant may may aware Screening Mini Mental State Exam ( MMSE ) score 24 Additional inclusion criterion sub study : Able willing travel PET image center complete plan scan session Past plan exposure ionizing radiation exceed safe permissible level Other prior current neurologic medical disorder may currently course study impair cognition psychiatric function A history stroke A documented history transient ischemic attack within last 12 month History schizophrenia , schizoaffective bipolar disorder Currently meet criterion major depression Within last 2 year , unstable clinical significant cardiovascular disease ( myocardial infarction , angina pectoris ) Additional exclusion criterion sub study : Inclusion research and/or medical protocol involve PET ligand radioactive agent within 12 month Present plan participation research and/or medical protocol involve PET ligand radioactive agent study WN25203 Have plan planning exposure ionize radiation combination plan administration study amyloid PET ligand would result cumulative exposure exceed local recommend exposure limit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>